Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 1
R&D Momentum
65/100
Pipeline Velocity
32/100
Trial Completion Rate
71/100
Pipeline Concentration
100/100
Pipeline Freshness
62/100
Activity
Last 14 days
Early Life Stress and Depression: Molecular and Functional Imaging
Novel Treatment Targets For Affective Disorders Through Cross-Species Investigation of Approach/Avoidance Decision Making
Synaptic Mechanisms of Intermittent Theta Burst Stimulation for Major Depressive Disorder
SPARC-LI: Synaptic Plasticity Augmented Rapid Circuit Stimulation
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
Effectiveness of HabitWorks and Symptom Tracking for Anxiety and Depression
Earlier
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)